Roughly a year ago, Gilead Sciences revealed that it was laying off about 7% of Kite Pharma’s workforce in a bid to refresh its cell therapy subsidiary. Now, the Foster City, California-based pharma—best known for its HIV medicines—is telegraphing another round of job cuts.
Gilead will lay off 72 staffers in Seattle starting Jan. 17, according to a Worker Adjustment and Retraining Notification alert filed with the state of Washington. Gilead’s lone Seattle office, which the company is also closing down, focuses on “supporting research and clinical development,” according to the company’s website.
Gilead employed some 230 people in Washington out of a total workforce of 18,000 as of March, the Puget Sound Business Journal reported earlier this year.
“We are closing our Seattle office as part of our efforts to align resources with our long-term strategic goals,” a Gilead spokesperson told Fierce Biotech Thursday. “This…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
U.S. Schools and Child Care Centers Invited to Reconnect Children With Nature Through $25,000 Outdoor Classroom Contest
FORT COLLINS, Colo., Sept. 19, 2025 /PRNewswire/ – There is a new era in education, and it’s outdoors. Exposure to nature while learning and engaging all the senses increases retention, test scores, and improves physical […]
STAT+: Amgen sues Colorado over its prescription drug affordability board
Amgen has filed a lawsuit accusing a Colorado state board of violating the U.S. Constitution over a plan to pursue a first-in-the-nation move to cap the cost of a pricey prescription medicine. In its lawsuit, […]
Federal changes could mean more turbulence in health care
If lawmakers can’t reach a deal on ACA tax credits — and possibly even if they do — there are major implications for the entire health-care sector. Click here to view original post Click Here […]
